Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials-Reference-Cited by-同舟云学术

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials

Published:2009-03-22 Issue:2 Volume:11 Page:111-119
ISSN:1523-3774
Container-title:Current Rheumatology Reports
language:en
Short-container-title:Curr Rheumatol Rep

Author:

Au Karen,Khanna Dinesh,Clements Philip J.,Furst Daniel E.,Tashkin Donald P.

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s11926-009-0016-2.pdf

Reference62 articles.

1. Steen VD, Medsger TA Jr: Changes in causes of death in systemic sclerosis. Ann Rheum Dis 2007, 66:940–944.

2. Beon M, Harley RA, Wessels A, et al.: Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 2004, 22:733–742.

3. Scala E, Pallotta S, Frezzolini A, et al.: Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540–546.

4. Bogatkevich GS, Gustilo E, Oates JC, et al.: Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005, 288:L190–L201.

5. Shi-Wen X, Chen Y, Denton CP, et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15:2707–2719.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease;Revista Colombiana de Reumatología (English Edition);2024-04

2. An overview of screening, treatment, and next steps in research in rheumatoid arthritis interstitial lung disease;Revista Colombiana de Reumatología;2023-09

3. Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: A meta-analysis and bioinformatics analysis;Frontiers in Immunology;2022-11-30

4. Krebs von den Lungen-6 (KL-6), soluble programmed cell death-1 (sPD-1) and its ligand-1(sPDL-1) in systemic sclerosis patients: Relation to disease parameters;The Egyptian Rheumatologist;2022-10

5. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis;Frontiers in Immunology;2021-12-09